L. A. Hammond

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

Anthony W. Tolcher, Stanton L. Gerson, Christiane Geyer et al. · British Journal of Cancer · 2003 · 366 citations · Full text

Dna Damage, Molecular Biology, Pathology +18

Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.

Eric K. Rowinsky, Lee Smith, Y M Wang et al. · Journal of Clinical Oncology · 1998 · 146 citations

A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.

Carolyn D. Britten, Eric K. Rowinsky, Sharyn D. Baker et al. · PubMed · 1999 · 70 citations

Immunology, Pharmacokinetic Study, Pharmacotherapy +16

Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity

Johann S. de Bono, Sun Young Rha, Joseph Stephenson et al. · Annals of Oncology · 2004 · 68 citations · Full text

Cancer Immunosurveillance, Medicine, Immunology +8

Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (IressaTM), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR)

Mark G. Kris, Roy S. Herbst, Danny Rischin et al. · Lung Cancer · 2000 · 63 citations

Oncology, Objective Regressions, Medicine +9